Balyasny Asset Management
FATE icon

Balyasny Asset Management’s Fate Therapeutics FATE Stock Holding History

Balyasny Asset Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-39,836
Closed -$149K – 2773
2023
Q4 		$149K Sell
39,836
-106,316
-73% -$251K ﹤0.01% 2349
2023
Q3 		$310K Sell
146,152
-85,643
-37% -$284K ﹤0.01% 1903
2023
Q2 		$1.1M Buy
231,795
+62,939
+37% +$347K ﹤0.01% 1584
2023
Q1 		$962K Buy
+168,856
New +$1.02M ﹤0.01% 1750
2018
Q2 		– Sell
-13,828
Closed -$135K – 1881
2018
Q1 		$135K Sell
13,828
-28,081
-67% -$269K ﹤0.01% 1804
2017
Q4 		$256K Buy
41,909
+30,311
+261% +$135K ﹤0.01% 1806
2017
Q3 		$46K Buy
+11,598
New +$39.4K ﹤0.01% 1821

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $4.85B AUM 144% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return